{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T16:54:15Z","timestamp":1778691255043,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003645","name":"National Cancer Center","doi-asserted-by":"publisher","award":["No.1532200-3"],"award-info":[{"award-number":["No.1532200-3"]}],"id":[{"id":"10.13039\/501100003645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s10549-018-4740-z","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T22:11:09Z","timestamp":1520460669000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay"],"prefix":"10.1007","volume":"170","author":[{"given":"Soo Jin","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moo Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun-Young","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi Kyung","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungnam","family":"Joo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youngmee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Gyeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai Hong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hoon","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So-Youn","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seeyoun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keun Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In Hae","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1122-8230","authenticated-orcid":false,"given":"Eun Sook","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"key":"4740_CR1","doi-asserted-by":"crossref","unstructured":"Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK (2017) AJCC Cancer Staging manual 8th edn., pp. 589\u2013627","DOI":"10.1007\/978-3-319-40618-3"},{"issue":"23","key":"4740_CR2","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24(23):3726\u20133734","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"4740_CR3","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F (2015) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(suppl 5):v8\u2013v30","journal-title":"Ann Oncol"},{"key":"4740_CR4","unstructured":"Excellence NIfHaC (2016) NICE Guidance: breast cancer \n                    https:\/\/www.nice.org.uk\/guidance\/qs12\/resources\/breast-cancer-pdf-2098481951941\n                    \n                  . Accessed 1 Nov 2017"},{"issue":"8","key":"4740_CR5","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Th\u00fcrlimann B, Senn H-J, Andr\u00e9 F, Baselga J (2015) Tailoring therapies\u2014improving the management of early breast cancer: St Gallen International expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26(8):1533\u20131546","journal-title":"Ann Oncol"},{"key":"4740_CR6","unstructured":"Health G (2017) About the Oncotype DX Breast Recurrence Score Test. \n                    http:\/\/www.oncotypeiq.com\/en-US\/breast-cancer\/healthcare-professionals\/oncotype-dx-breast-recurrence-score\/about-the-test\n                    \n                  . Accessed 1 Nov 2017"},{"key":"4740_CR7","unstructured":"NCCN guidelines: breast cancer. Version 2. (2017) \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf\n                    \n                  . Accessed 1 Nov 2017"},{"issue":"11","key":"4740_CR8","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/bjc.2013.207","volume":"108","author":"S Holt","year":"2013","unstructured":"Holt S, Bertelli G, Humphreys I, Valentine W, Durrani S, Pudney D, Rolles M, Moe M, Khawaja S, Sharaiha Y (2013) A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK. Br J Cancer 108(11):2250\u20132258","journal-title":"Br J Cancer"},{"issue":"3","key":"4740_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s10549-010-1243-y","volume":"127","author":"M Kondo","year":"2011","unstructured":"Kondo M, Hoshi S-L, Yamanaka T, Ishiguro H, Toi M (2011) Economic evaluation of the 21-gene signature (Oncotype DX\u00ae) in lymph node-negative\/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat 127(3):739\u2013749","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"4740_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10549-016-3926-5","volume":"159","author":"BM Parsons","year":"2016","unstructured":"Parsons BM, Landercasper J, Smith AL, Go RS, Borgert AJ, Dietrich LL (2016) 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010\u20132013. Breast Cancer Res Treat 159(2):315\u2013326","journal-title":"Breast Cancer Res Treat"},{"issue":"21","key":"4740_CR11","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","volume":"373","author":"JA Sparano","year":"2015","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005\u20132014","journal-title":"N Engl J Med"},{"issue":"20","key":"4740_CR12","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1200\/JCO.2015.63.5383","volume":"34","author":"O Gluz","year":"2016","unstructured":"Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, Kraemer S, Aktas B, Kuemmel S, Reimer T (2016) West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 34(20):2341\u20132349","journal-title":"J Clin Oncol"},{"issue":"4","key":"4740_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1524-4733.2010.00724.x","volume":"13","author":"SH Klang","year":"2010","unstructured":"Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J (2010) Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13(4):381\u2013387","journal-title":"Value Health"},{"issue":"10","key":"4740_CR14","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1200\/JCO.2008.20.2119","volume":"28","author":"SS Lo","year":"2010","unstructured":"Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10):1671\u20131676","journal-title":"J Clin Oncol"},{"issue":"3","key":"4740_CR15","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10549-010-1329-6","volume":"126","author":"FO Ademuyiwa","year":"2011","unstructured":"Ademuyiwa FO, Miller A, O\u2019Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S (2011) The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 126(3):797\u2013802","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"4740_CR16","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1634\/theoncologist.2011-0045","volume":"16","author":"JE Joh","year":"2011","unstructured":"Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, Soliman H, Boughey JC, Reynolds C, Lawton TJ (2011) The effect of oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncologist 16(11):1520\u20131526","journal-title":"Oncologist"},{"issue":"3","key":"4740_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/annonc\/mdr278","volume":"23","author":"J Albanell","year":"2011","unstructured":"Albanell J, Gonzalez A, Ruiz-Borrego M, Alba E, Garcia-Saenz J, Corominas J, Burgues O, Furio V, Rojo A, Palacios J (2011) Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol 23(3):625\u2013631","journal-title":"Ann Oncol"},{"issue":"3","key":"4740_CR18","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/annonc\/mds512","volume":"24","author":"W Eiermann","year":"2012","unstructured":"Eiermann W, Rezai M, K\u00fcmmel S, K\u00fchn T, Warm M, Friedrichs K, Schneeweiss A, Markmann S, Eggemann H, Hilfrich J (2012) The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol 24(3):618\u2013624","journal-title":"Ann Oncol"},{"issue":"2","key":"4740_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4143\/crt.2013.223","volume":"47","author":"MH Lee","year":"2015","unstructured":"Lee MH, Han W, Lee JE, Kim KS, Park H, Kim J, Bae SY, Shin HJ, Lee JW, Lee ES (2015) The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea. Cancer Res Treat 47(2):208","journal-title":"Cancer Res Treat"},{"issue":"5","key":"4740_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.ejso.2016.12.010","volume":"43","author":"J Loncaster","year":"2017","unstructured":"Loncaster J, Armstrong A, Howell S, Wilson G, Welch R, Chittalia A, Valentine W, Bundred N (2017) Impact of Oncotype DX breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK. Eur J Surg Oncol (EJSO) 43(5):931\u2013937","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"10","key":"4740_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/modpathol.2008.54","volume":"21","author":"MB Flanagan","year":"2008","unstructured":"Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R (2008) Histopathologic variables predict Oncotype DX\u2122 recurrence score. Mod Pathol 21(10):1255","journal-title":"Mod Pathol"},{"issue":"12","key":"4740_CR22","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ejca.2004.02.025","volume":"40","author":"P Ed\u00e9n","year":"2004","unstructured":"Ed\u00e9n P, Ritz C, Rose C, Fern\u00f6 M, Peterson C (2004) \u201cGood Old\u201d clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40(12):1837\u20131841","journal-title":"Eur J Cancer"},{"issue":"16","key":"4740_CR23","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1016\/j.ejca.2006.06.031","volume":"42","author":"E Nim\u00e9us-Malmstr\u00f6m","year":"2006","unstructured":"Nim\u00e9us-Malmstr\u00f6m E, Ritz C, Ed\u00e9n P, Johnsson A, Ohlsson M, Strand C, \u00d6stberg G, Fern\u00f6 M, Peterson C (2006) Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. Eur J Cancer 42(16):2729\u20132737","journal-title":"Eur J Cancer"},{"key":"4740_CR24","unstructured":"SWOG (2012) SWOG RxPONDER Trial (S1007). \n                    http:\/\/www.swog.org\/Visitors\/S1007\/patients.asp\n                    \n                  . Accessed 1 Nov 2017"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-4740-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4740-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4740-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T19:41:40Z","timestamp":1551987700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-4740-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["4740"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-4740-z","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,8]]},"assertion":[{"value":"27 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors report that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals. The study protocol was approved by the institutional review board of the National Cancer Center (NCC 2018-0007).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}